Idorsia Ltd (OTCMKTS:IDRSF – Get Free Report) shares dropped 0.2% during mid-day trading on Thursday . The company traded as low as $6.24 and last traded at $6.24. Approximately 400 shares traded hands during trading, a decline of 96% from the average session volume of 10,816 shares. The stock had previously closed at $6.25.
Wall Street Analysts Forecast Growth
Separately, Deutsche Bank Aktiengesellschaft restated a “hold” rating on shares of Idorsia in a research report on Monday, August 3rd. One analyst has rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Idorsia has a consensus rating of “Moderate Buy”.
Get Our Latest Research Report on Idorsia
Idorsia Price Performance
Idorsia Company Profile
Idorsia Ltd is a Swiss biopharmaceutical company founded in 2017 as a spin-off from Actelion following its acquisition by Johnson & Johnson. Headquartered in Allschwil, Switzerland, Idorsia focuses on the discovery, development and commercialization of innovative small-molecule therapeutics. The company’s R&D efforts span multiple therapeutic areas, including neuroscience, cardiovascular and immunology, with the goal of addressing unmet medical needs through novel mechanisms of action.
Among Idorsia’s lead products is daridorexant, a dual orexin receptor antagonist developed for the treatment of insomnia.
See Also
- Five stocks we like better than Idorsia
- The Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth Story
- NVIDIA’s Hugging Face Deal Raises a Bigger Question About Its AI Moat Now
- Dropping the Dough: Yum! Brands Strategically Trims the Fat
- These 3 Stock Charts Just Flashed the Dreaded Death Cross Pattern
Receive News & Ratings for Idorsia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Idorsia and related companies with MarketBeat.com's FREE daily email newsletter.
